What is the recommended management of diabetic ketoacidosis?

Management of Diabetic Ketoacidosis

For moderate-to-severe DKA, continuous intravenous insulin infusion is the preferred treatment regimen, while patients with mild DKA can be managed with subcutaneous insulin injections. 1

Initial Assessment and Diagnosis

Confirm DKA diagnosis with the triad:

• Metabolic acidosis: pH <7.3, serum bicarbonate <18 mEq/L, anion gap >10 mEq/L 1, 2
• Elevated ketones: Serum or urine ketones present (β-hydroxybutyrate preferred over nitroprusside method) 1
• Hyperglycemia: Blood glucose >250 mg/dL (though euglycemic DKA is increasingly recognized, particularly with SGLT2 inhibitor use) 2

Obtain initial laboratory workup: Blood glucose, venous blood gases, electrolytes (particularly potassium), BUN, creatinine, calcium, phosphorus, urinalysis, complete blood count, A1C, and ECG 1, 2

Fluid Resuscitation

Initiate aggressive intravenous fluid replacement immediately - this is the first critical step before insulin therapy 3

• Start with isotonic normal saline for initial volume resuscitation 4
• Administer approximately 1.5 times the 24-hour maintenance requirements (5 mL/kg/h), not exceeding two times maintenance 1
• Adjust fluid type based on serum sodium and hemodynamic status to avoid cerebral edema from overly rapid osmolality correction 1

Insulin Therapy

For Moderate-to-Severe DKA:

Use continuous intravenous insulin infusion 1

• Begin insulin only after confirming adequate potassium levels (see electrolyte management below) 1
• Standard dosing: Continuous IV infusion at 0.1 units/kg/h 1
• When blood glucose falls below 14 mmol/L (252 mg/dL), reduce FRIII to 0.05 units/kg/h and add 10% dextrose to prevent hypoglycemia while continuing ketone clearance 5

For Mild DKA:

Subcutaneous or intramuscular regular insulin is equally effective 1

• Priming dose: 0.4-0.6 units/kg body weight (half IV bolus, half SC/IM) 1
• Maintenance: 0.1 unit/kg regular insulin SC or IM every hour 1

Electrolyte Management

Potassium Replacement (Critical Priority):

Monitor potassium closely - hypokalaemia occurs in approximately 50% of cases and severe hypokalaemia (<2.5 mEq/L) increases mortality 1

• Potassium solution composition: 1/3 potassium phosphate and 2/3 potassium chloride or acetate 1
• Replace potassium aggressively throughout treatment to prevent cardiac complications 1

Phosphate:

Routine phosphate replacement has not shown clinical benefit 1

• Consider careful phosphate replacement only in specific situations: cardiac dysfunction, anemia, respiratory depression, or serum phosphate <1.0 mg/dL 1

Bicarbonate:

Bicarbonate therapy is generally not recommended due to risks of worsening ketosis, hypokalaemia, and cerebral edema 4

• Consider bicarbonate only if pH <6.9 or when pH <7.0 after initial hour of hydration 1
• If indicated: Administer 1-2 mEq/kg sodium bicarbonate over 1 hour 1

Monitoring During Treatment

Draw blood every 2-4 hours for serum electrolytes, glucose, BUN, creatinine, osmolality, and venous pH 1

Use venous pH rather than repeated arterial blood gases - venous pH correlates well (typically 0.03 units lower) and is less invasive 1

Monitor β-hydroxybutyrate levels, not nitroprusside ketone measurements - nitroprusside only detects acetoacetic acid and acetone, missing the predominant ketoacid (β-hydroxybutyrate), which can falsely suggest worsening ketosis during treatment 1

Resolution Criteria

DKA is resolved when ALL of the following are met: 1

• Blood glucose <200 mg/dL
• Serum bicarbonate ≥18 mEq/L
• Venous pH ≥7.3
• Normal anion gap

Transition to Subcutaneous Insulin

Critical timing to prevent rebound hyperglycemia:

• Continue IV insulin infusion for 1-2 hours AFTER starting subcutaneous insulin to ensure adequate plasma insulin levels 1
• Abrupt discontinuation of IV insulin without overlap causes poor glycemic control 1
• Initiate multiple-dose subcutaneous regimen combining short- or rapid-acting with intermediate- or long-acting insulin when patient can eat 1

Special Considerations and Pitfalls

Cerebral Edema Prevention:

Avoid rapid overcorrection of hyperglycemia and osmolality - gradual correction with judicious use of isotonic or hypotonic saline based on sodium levels prevents this rare but devastating complication 1, 4

SGLT2 Inhibitor-Associated DKA:

SGLT2 inhibitors modestly increase DKA risk, including euglycemic DKA 2

• Recognize that normal glucose does not exclude DKA in SGLT2 inhibitor users 2
• Traditional FDA guidance recommends withholding SGLT2 inhibitors 3 days preoperatively, though recent evidence suggests this may not be necessary for emergency surgery 6

Common Management Errors:

• Premature termination of IV insulin before ketone clearance 3
• Insufficient timing or dosing of subcutaneous insulin before stopping IV insulin 3
• Failure to reduce insulin infusion rate when glucose normalizes, leading to hypoglycemia while ketones persist 5
• Delayed adjustment of FRIII when implementing rate reduction protocols 5

Airway Management in Critically Ill Patients:

For impending respiratory failure, intubation with mechanical ventilation is recommended - BiPAP is contraindicated due to aspiration risk 4

• Consider IV sodium bicarbonate pre- and post-intubation if pH <7.2 or bicarbonate <10 mEq/L to prevent metabolic acidosis and hemodynamic collapse from apnea during intubation 4

Early Nutrition:

Initiate oral nutrition early when tolerated - this reduces ICU and overall hospital length of stay 4